Search details
1.
A possible case of serum sickness after ocrelizumab infusion.
Mult Scler
; 27(1): 155-158, 2021 01.
Article
in English
| MEDLINE | ID: mdl-32427524
2.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Int J Neurosci
; 127(5): 396-403, 2017 May.
Article
in English
| MEDLINE | ID: mdl-27143245
3.
Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
Int J Neurosci
; 127(11): 971-980, 2017 Nov.
Article
in English
| MEDLINE | ID: mdl-28100092
4.
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
Ann Neurol
; 78(1): 115-27, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25914168
5.
Eosinophilic fasciitis-like disorder developing in the setting of multiple sclerosis therapy.
J Drugs Dermatol
; 13(9): 1144-7, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-25226017
6.
Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis.
Mult Scler Relat Disord
; 54: 103086, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34289435
7.
Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis.
Mult Scler J Exp Transl Clin
; 7(2): 20552173211010832, 2021.
Article
in English
| MEDLINE | ID: mdl-33996142
8.
An argument for broad use of high efficacy treatments in early multiple sclerosis.
Neurol Neuroimmunol Neuroinflamm
; 7(1)2020 01.
Article
in English
| MEDLINE | ID: mdl-31757815
9.
Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis.
Mult Scler Int
; 2020: 5471987, 2020.
Article
in English
| MEDLINE | ID: mdl-33381316
10.
COVID-19 in teriflunomide-treated patients with multiple sclerosis.
J Neurol
; 267(10): 2790-2796, 2020 Oct.
Article
in English
| MEDLINE | ID: mdl-32494856
11.
Role of iron in neurotoxicity: a cause for concern in the elderly?
Curr Opin Clin Nutr Metab Care
; 12(1): 22-9, 2009 Jan.
Article
in English
| MEDLINE | ID: mdl-19057183
12.
Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.
J Neurol
; 265(11): 2688-2694, 2018 Nov.
Article
in English
| MEDLINE | ID: mdl-30203314
13.
Experience with long-term rituximab use in a multiple sclerosis clinic.
Mult Scler J Exp Transl Clin
; 2: 2055217316672100, 2016.
Article
in English
| MEDLINE | ID: mdl-28607739
14.
Iron and multiple sclerosis.
Neurobiol Aging
; 35 Suppl 2: S51-8, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-24929968
15.
Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab.
Neurol Neuroimmunol Neuroinflamm
; 6(5)2019 09.
Article
in English
| MEDLINE | ID: mdl-31454764
16.
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2.
Neuroreport
; 25(14): 1156-61, 2014 Oct 01.
Article
in English
| MEDLINE | ID: mdl-25100554
17.
Role of immunosuppressive therapy for the treatment of multiple sclerosis.
Neurotherapeutics
; 10(1): 77-88, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23271506
18.
The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis.
J Neuroimaging
; 22(2): 122-8, 2012 Apr.
Article
in English
| MEDLINE | ID: mdl-21447024
19.
Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate.
Neurol Neuroimmunol Neuroinflamm
; 3(5): e274, 2016 Oct.
Article
in English
| MEDLINE | ID: mdl-27606353
20.
Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis.
J Neuroimaging
; 21(2): e50-6, 2011 Apr.
Article
in English
| MEDLINE | ID: mdl-19888926
Results
1 -
20
de 20
1
Next >
>>